Irwin Gelman

[Irwin Gelman @IrwinGelman]

@nytimes Saw it. Can't wait until the three of you visit the next time. Xxxooo

[Irwin Gelman @IrwinGelman]

#WhyIRide, #RideToEndCancer, #EndCancer #RideForRoswell. Sign up for Team Gene Machine (the Cancer Crushers) to participate in the Ride for Roswell at https://t.co/ExtzsKR6Ir

[Irwin Gelman @IrwinGelman]

Please donate now to the Ride for Roswell!! #RFR19 Here's my personal page: https://t.co/qFS7YKQNR6

[Irwin Gelman @IrwinGelman]

Just published a paper in Oncotarget: SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk

https://t.co/9NPXmDuiL2

[Irwin Gelman @IrwinGelman]

Just published a paper in PLoS One: A methyl-sensitive element induces bidirectional transcription in TATA-less CpG island-associated promoters.
https://t.co/eUPwBwi7lT

[Irwin Gelman @IrwinGelman]

#IVResearch very important for metCa community to lobby local, state and US pols to pass increase in NCI budget for FY17 and more

[Irwin Gelman @IrwinGelman]

#IVResearch your tax dollars at work!

[Irwin Gelman @IrwinGelman]

#IVResearch great to hear about updating https://t.co/V9VOVbEbjY; was too technical for lay audience before

[Irwin Gelman @IrwinGelman]

#IVResearch Yes. Good PhI includes any response, incl to mets. But cohorts are very small, not powered

[Irwin Gelman @IrwinGelman]

#IVResearch NCI is best suited to fund metCa trials; biotechs want drugs that get quick FDA approval for niche cancer application

[Irwin Gelman @IrwinGelman]

#IVResearch Yes. Prostate, because recurrent metCa is the only lethal phenotype

[Irwin Gelman @IrwinGelman]

#IVResearch there are trials in https://t.co/mGl83sqDin with metCa as an endpoint. Need to check although few.

[Irwin Gelman @IrwinGelman]

#IVResearch Few drugs are specifically developed with metCa as a therapeutic endpoint; too costly, too much time needed.

[Irwin Gelman @IrwinGelman]

#IVResearch Correct about PhI trials- most have met disease but endpoint of trial is ONLY tox; if shows benefit, they can ask to continue

[Irwin Gelman @IrwinGelman]

@LynnetteLayman which trial specifically?

[Irwin Gelman @IrwinGelman]

#IVResearch However, these combos, which hit proliferation mechanisms, still will not hit stem cells, which are quiescent

[Irwin Gelman @IrwinGelman]

#IVResearch Many trials pairing targeted drugs with standard chemos

[Irwin Gelman @IrwinGelman]

#IVResearch Pembrolizumab (Keytruda), Nivolumab (Opdivo), Atezolizumab (Tecentriq): approved or in PhIII clinical trials

[Irwin Gelman @IrwinGelman]

#IVResearch Great progress with immune checkpoint inhibitors, but only in some cancers:

[Irwin Gelman @IrwinGelman]

#IVResearch This is not typically covered by insurance, meaning high out-of-pocket costs